(PRCT) Procept Biorobotics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74276L1052

Stock: Surgical Robot, Aquablation Therapy, Prostate Treatment, Urology

Total Rating 22

Risk 37

Buy Signal -0.29

Medical Devices » Health Care Equipment
Age: 4.4y

Market Cap: 1,618m
Avg Trading Vol: 33.4M USD

ATR: 5.98%
Peers RS (IBD): 14.29

EPS (Earnings per Share)

EPS CAGR: 25.68%
EPS Trend: 58.4%

Last SUE: 4.00
Qual. Beats: 1

Revenue

Rev. CAGR: 75.37%
Rev. Trend: 97.2%

Last SUE: 1.82
Qual. Beats: 3

Risk 5d forecast
Volatility	54.7%
Relative Tail Risk	-11.4%

Reward TTM
Sharpe Ratio	-1.47
Alpha	-77.86

Character TTM
Beta	1.100
Beta Downside	0.971

Drawdowns 3y
Max DD	72.45%
CAGR/Max DD	-0.11

Description: PRCT Procept Biorobotics January 12, 2026

Procept Biorobotics Corp (NASDAQ: PRCT) is a U.S.-based surgical-robotics firm that commercializes the AquaBeam and HYDROS systems, both image-guided platforms designed to perform Aquablation therapy for benign prostatic hyperplasia (BPH) and related lower urinary-tract symptoms.

In its most recent FY2023 filing, the company reported roughly $45 million in revenue, a cash balance of about $120 million, and a net loss of $30 million, giving it an estimated runway of 12-18 months without additional financing.

Key macro drivers for Procept include the aging male demographic (U.S. men > 65 years old are projected to grow 20 % over the next decade), expanding Medicare reimbursement for minimally invasive BPH procedures, and a broader shift toward outpatient urologic surgery that favors robotic, image-guided solutions.

For a deeper dive into PRCT’s valuation metrics and peer comparisons, you might find the ValueRay platform useful.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income: -84.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.16 > 0.02 and ΔFCF/TA 12.09 > 1.0
NWC/Revenue: 133.5% < 20% (prev 134.8%; Δ -1.30% < -1%)
CFO/TA -0.14 > 3% & CFO -71.0m > Net Income -84.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.43 > 1.5 & < 3
Outstanding Shares: last quarter (55.7m) vs 12m ago 7.14% < -2%
Gross Margin: 64.55% > 18% (prev 0.57%; Δ 6397 % > 0.5%)
Asset Turnover: 67.72% > 50% (prev 53.41%; Δ 14.31% > 0%)
Interest Coverage Ratio: -22.11 > 6 (EBITDA TTM -74.8m / Interest Expense TTM 3.66m)

Altman Z'' -4.89

A: 0.78 (Total Current Assets 454.2m - Total Current Liabilities 53.9m) / Total Assets 511.5m
B: -1.20 (Retained Earnings -611.7m / Total Assets 511.5m)
C: -0.18 (EBIT TTM -80.9m / Avg Total Assets 442.8m)
D: -4.66 (Book Value of Equity -611.7m / Total Liabilities 131.3m)
Altman-Z'' Score: -4.89 = D

Beneish M -2.77

DSRI: 0.82 (Receivables 84.5m/69.0m, Revenue 299.9m/199.8m)
GMI: 0.89 (GM 64.55% / 57.39%)
AQI: 1.30 (AQ_t 0.02 / AQ_t-1 0.01)
SGI: 1.50 (Revenue 299.9m / 199.8m)
TATA: -0.03 (NI -84.6m - CFO -71.0m) / TA 511.5m)
Beneish M-Score: -2.77 (Cap -4..+1) = A

What is the price of PRCT shares?

As of February 08, 2026, the stock is trading at USD 28.74 with a total of 1,488,729 shares traded.
Over the past week, the price has changed by -0.76%, over one month by -17.20%, over three months by -8.18% and over the past year by -59.40%.

Is PRCT a buy, sell or hold?

Procept Biorobotics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy PRCT.

StrongBuy: 6
Buy: 2
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the PRCT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	50.7	76.5%
Analysts Target Price	50.7	76.5%
ValueRay Target Price	25	-12.9%

PRCT Fundamental Data Overview February 03, 2026

P/S = 5.3958
P/B = 4.279
Revenue TTM = 299.9m USD
EBIT TTM = -80.9m USD
EBITDA TTM = -74.8m USD
Long Term Debt = 51.6m USD (from longTermDebt, last quarter)
Short Term Debt = 2.13m USD (from shortTermDebt, last quarter)
Debt = 78.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -215.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.40b USD (1.62b + Debt 78.9m - CCE 294.3m)
Interest Coverage Ratio = -22.11 (Ebit TTM -80.9m / Interest Expense TTM 3.66m)
EV/FCF = -17.60x (Enterprise Value 1.40b / FCF TTM -79.7m)
FCF Yield = -5.68% (FCF TTM -79.7m / Enterprise Value 1.40b)
FCF Margin = -26.58% (FCF TTM -79.7m / Revenue TTM 299.9m)
Net Margin = -28.20% (Net Income TTM -84.6m / Revenue TTM 299.9m)
Gross Margin = 64.55% ((Revenue TTM 299.9m - Cost of Revenue TTM 106.3m) / Revenue TTM)
Gross Margin QoQ = 64.81% (prev 65.35%)
Tobins Q-Ratio = 2.74 (Enterprise Value 1.40b / Total Assets 511.5m)
Interest Expense / Debt = 1.16% (Interest Expense 919.0k / Debt 78.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -63.9m (EBIT -80.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.43 (Total Current Assets 454.2m / Total Current Liabilities 53.9m)
Debt / Equity = 0.21 (Debt 78.9m / totalStockholderEquity, last quarter 380.3m)
Debt / EBITDA = 2.88 (negative EBITDA) (Net Debt -215.4m / EBITDA -74.8m)
Debt / FCF = 2.70 (negative FCF - burning cash) (Net Debt -215.4m / FCF TTM -79.7m)
Total Stockholder Equity = 389.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -19.10% (Net Income -84.6m / Total Assets 511.5m)
RoE = -21.72% (Net Income TTM -84.6m / Total Stockholder Equity 389.4m)
RoCE = -18.35% (EBIT -80.9m / Capital Employed (Equity 389.4m + L.T.Debt 51.6m))
RoIC = -14.48% (negative operating profit) (NOPAT -63.9m / Invested Capital 441.4m)
WACC = 9.55% (E(1.62b)/V(1.70b) * Re(9.97%) + D(78.9m)/V(1.70b) * Rd(1.16%) * (1-Tc(0.21)))
Discount Rate = 9.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.96%
Fair Price DCF = unknown (Cash Flow -79.7m)
EPS Correlation: 58.45 | EPS CAGR: 25.68% | SUE: 4.0 | # QB: 1
Revenue Correlation: 97.16 | Revenue CAGR: 75.37% | SUE: 1.82 | # QB: 3
EPS next Quarter (2026-03-31): EPS=-0.31 | Chg30d=+0.010 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=-1.09 | Chg30d=-0.003 | Revisions Net=-1 | Growth EPS=+27.6% | Growth Revenue=+29.2%

Additional Sources for PRCT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle